Pfizer & Bend collaborating on osteoarthritis nanoparticle drug delivery

By Nick Taylor

- Last updated on GMT

Related tags: Bend research

Bend Research is developing a nanoparticle drug delivery system for treating osteoarthritis in a “close collaboration” with Pfizer.

Current treatments for osteoarthritis suffer from a lack of effective drugs and inability to keep the treatment at the site of action. By bringing together Pfizer’s novel therapeutic active agents and Bend Research’s drug delivery technologies the collaborators hope to tackle both problems.

[Our system] forms a loose net gel which maintains the nanoparticles within [the knee] cavity for an extended period of time​”, Michael Morgan, director of new technologies at Bend Research, told in-PharmaTechnologist.

Bend has tested the nanoparticle drug delivery system in-vitro ​and done initial studies in the knee joints of rodents. The next steps are to extend these studies to longer durations and do more work on controlling the release of the molecules.

Related news

Show more

Related products

show more

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Local lab Data Management

Local lab Data Management

Q² Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Related suppliers

Follow us

Products

View more

Webinars